- Gene editor Scribe starts second-half IPO spree with $129M listingA 9-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna is kicking off a run of biotech IPOs set for this year's second half. Scribe Therapeutics priced its $128.7 millionEndpoints · 7h ago↗ source
- Scribe records upsized $129M IPO to bankroll lipid-lowering genetic medsIn vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.Fierce Biotech · 8h ago↗ source
- STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptidesThe panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.STAT